Compare
Huntsman Corp vs Chemours Co vs FMC Corp vs Innospec Inc.
| Latest fiscal year | Huntsman Corp HUN | Chemours Co CC | FMC Corp FMC | Innospec Inc. IOSP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.68B | $5.81B | $3.47B | $1.78B |
| Revenue growth (YoY) | -5.8% | +0.4% | -18.3% | -3.7% |
| Gross margin | 13.2% | 15.5% | 37.0% | 27.7% |
| Operating margin | -2.3% | n/a | -47.0% | 7.3% |
| Net margin | -5.0% | -6.6% | -64.6% | 6.6% |
| Net income | -$284.00M | -$386.00M | -$2.24B | $116.60M |
| EPS (Diluted) | -$1.65 | -$2.57 | -$17.88 | $4.67 |
| Operating cash flow | $289.00M | $264.00M | -$6.20M | $138.30M |
| Free cash flow | $116.00M | $51.00M | -$102.50M | n/a |
| Cash & equivalents | $429.00M | $670.00M | $584.50M | $292.50M |
| Total assets | $7.01B | $7.38B | $9.69B | $1.83B |
| Total liabilities | $4.06B | $7.13B | n/a | $499.50M |
| Shareholders' equity | $2.96B | $251.00M | $2.10B | $1.33B |
| Return on year-end equity | -9.6% | -153.8% | -106.7% | 8.8% |
| Shares outstanding | 172.62M | 149.89M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Huntsman Corp | Chemours Co | FMC Corp | Innospec Inc. |
|---|---|---|---|---|
| Latest | $5.68B Ended 2025-12-31 | $5.81B Ended 2025-12-31 | $3.47B Ended 2025-12-31 | $1.78B Ended 2025-12-31 |
| 1 year earlier | $6.04B Ended 2024-12-31 | $5.78B Ended 2024-12-31 | $4.25B Ended 2024-12-31 | $1.85B Ended 2024-12-31 |
| 2 years earlier | $6.11B Ended 2023-12-31 | $6.08B Ended 2023-12-31 | $4.49B Ended 2023-12-31 | $1.95B Ended 2023-12-31 |
| 3 years earlier | $8.02B Ended 2022-12-31 | $6.83B Ended 2022-12-31 | $5.80B Ended 2022-12-31 | $1.96B Ended 2022-12-31 |
| 4 years earlier | $7.67B Ended 2021-12-31 | $6.34B Ended 2021-12-31 | $5.05B Ended 2021-12-31 | $1.48B Ended 2021-12-31 |